



## **Cytotoxic dendritic cells generated from cancer patients.**

Daniela Lakomy, Nona Janikashvili, Jennifer Fraszczak, Malika Trad, Sylvain Audia, Maxime Samson, Marion Ciudad, Julien Vinit, Catherine Vergely, Denis Caillot, et al.

### **► To cite this version:**

Daniela Lakomy, Nona Janikashvili, Jennifer Fraszczak, Malika Trad, Sylvain Audia, et al.. Cytotoxic dendritic cells generated from cancer patients.. Journal of Immunology, 2011, 187 (5), pp.2775-82. 10.4049/jimmunol.1004146 . hal-00828336

**HAL Id: hal-00828336**

**<https://u-bourgogne.hal.science/hal-00828336>**

Submitted on 30 May 2013

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



This information is current as of May 30, 2013.

## Cytotoxic Dendritic Cells Generated from Cancer Patients

Daniela Lakomy, Nona Janikashvili, Jennifer Fraszczak, Malika Trad, Sylvain Audia, Maxime Samson, Marion Ciudad, Julien Vinit, Catherine Vergely, Denis Caillot, Pascal Foucher, Laurent Lagrost, Salem Chouaib, Emmanuel Katsanis, Nicolas Larmonier and Bernard Bonnotte

*J Immunol* 2011; 187:2775-2782; Prepublished online 29 July 2011;  
doi: 10.4049/jimmunol.1004146  
<http://www.jimmunol.org/content/187/5/2775>

**Supplementary Material** <http://www.jimmunol.org/content/suppl/2011/07/29/jimmunol.1004146.DC1.html>

**References** This article **cites 69 articles**, 33 of which you can access for free at:  
<http://www.jimmunol.org/content/187/5/2775.full#ref-list-1>

**Subscriptions** Information about subscribing to *The Journal of Immunology* is online at:  
<http://jimmunol.org/subscriptions>

**Permissions** Submit copyright permission requests at:  
<http://www.aai.org/ji/copyright.html>

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at:  
<http://jimmunol.org/cgi/alerts/etoc>



# Cytotoxic Dendritic Cells Generated from Cancer Patients

Daniela Lakomy,<sup>\*,1</sup> Nona Janikashvili,<sup>\*,1</sup> Jennifer Fraszczak,<sup>\*</sup> Malika Trad,<sup>\*</sup> Sylvain Audia,<sup>\*,†</sup> Maxime Samson,<sup>\*</sup> Marion Ciudad,<sup>\*</sup> Julien Vinit,<sup>\*</sup> Catherine Vergely,<sup>\*</sup> Denis Caillot,<sup>‡</sup> Pascal Foucher,<sup>§</sup> Laurent Lagrost,<sup>\*</sup> Salem Chouaib,<sup>¶</sup> Emmanuel Katsanis,<sup>||,\*,\*\*</sup> Nicolas Larmonier,<sup>||,\*,\*\*</sup> and Bernard Bonnotte<sup>\*,†,2</sup>

Known for years as professional APCs, dendritic cells (DCs) are also endowed with tumoricidal activity. This dual role of DC as killers and messengers may have important implications for tumor immunotherapy. However, the tumoricidal activity of DCs has mainly been investigated in animal models. Cancer cells inhibit antitumor immune responses using numerous mechanisms, including the induction of immunosuppressive/ tolerogenic DCs that have lost their ability to present Ags in an immunogenic manner. In this study, we evaluated the possibility of generating tumor killer DCs from patients with advanced-stage cancers. We demonstrate that human monocyte-derived DCs are endowed with significant cytotoxic activity against tumor cells following activation with LPS. The mechanism of DC-mediated tumor cell killing primarily involves peroxynitrites. This observed cytotoxic activity is restricted to immature DCs. Additionally, after killing, these cytotoxic DCs are able to activate tumor Ag-specific T cells. These observations may open important new perspectives for the use of autologous cytotoxic DCs in cancer immunotherapy strategies. *The Journal of Immunology*, 2011, 187: 2775–2782.

Dendritic cells (DCs) play a central role in the initiation and regulation of innate and adaptive immune responses. As such, they represent strategic elements of cancer vaccination approaches. In response to proinflammatory signals, DCs generated from patients' monocytes differentiate into activated cells that release cytokines and upregulate MHC class I, MHC class II, and costimulatory molecules. When appropriately loaded with tumor Ags, DCs are capable of presenting antigenic peptides and of activating tumor-specific T lymphocytes leading to specific antitumor immune responses (1). However, to date, only limited clinical responses have been obtained in trials evaluating the efficacy of DC-based tumor vaccines (2–7).

The possibility of improving the efficacy of DC-based cancer vaccines by triggering their direct tumor killing activity has not been evaluated. Several subsets of killer DCs (KDCs) have been described in mice (8–14), rats (15–22), and humans (23–49). However, few data concerning the killing ability of human DCs generated from cancer patients are available (26, 44, 49). In most human studies, KDCs were obtained by in vitro differentiation of monocytes from healthy donors in the presence of GM-CSF and IL-4 (23, 24, 27, 31, 32, 45, 46) followed by exposure to diverse inflammatory signals such as IFN- $\beta$  (35), IFN- $\gamma$  (27), LPS (27, 33, 46), imiquimod, polyinosinic:polycytidylic acid [poly(I:C)] (48), OK432 (penicillin-inactivated *Streptococcus pyogenes*) (30), or CD40L (33). The modes of induction (LPS, CpG, IFNs, and CD40L) and the effector mechanisms (Fas ligand [FasL], TNF family members) underlying the killing activity of these cells remain a subject of controversy (26, 29, 34, 35, 38, 44, 47, 48). Additionally, the ability of these KDCs to capture dead tumor cells and to induce specific T cell activation has not been fully elucidated. In terms of clinical applications, triggering of the cytotoxic activity of autologous DCs from cancer patients may further enhance their therapeutic potential by fostering the release of tumor Ags immediately available for capture and presentation to specific T cells. Clear evidence has been provided that cancers can inhibit the anti-tumor immune response by numerous mechanisms, including the induction of tolerogenic DCs. However, no information regarding the possible negative regulation of KDC cytotoxic activity by cancer cells is currently available. To address this question, in this study we investigated the possibility of generating human DCs endowed with tumor-killing activity from cancer patients.

Our results indicate that following activation with LPS, human monocyte-derived DCs generated from advanced-stage cancer patients are strongly cytotoxic against tumor cells. These human KDCs (hKDCs) were capable of triggering necrotic death of a wide variety of tumor cell lines through direct cell contact. The killing mechanism involves peroxynitrite release. Interestingly, immature but not mature DCs exhibit cytotoxic activity against cancer cells.

\*INSERM Unité Mixte de Recherche 866, Institut de Recherche Fédératif 100, Faculté de Médecine, 21079 Dijon, France; <sup>†</sup>Service de Médecine Interne et d'Immunologie, Hôpital du Bocage, 21000 Dijon, France; <sup>‡</sup>Service de Hématologie, Hôpital du Bocage, 21000 Dijon, France; <sup>§</sup>Service de Pneumologie, Hôpital du Bocage, 21000 Dijon, France; <sup>¶</sup>INSERM Unité 753, Institut de Cancérologie Gustave Roussy, 94800 Villejuif, France; <sup>||</sup>Department of Pediatrics and Immunobiology, Steele Children's Research Center, University of Arizona, Tucson, AZ 85724; <sup>\*\*</sup>BIO5 Institute, University of Arizona, Tucson, AZ 85724; and <sup>\*\*</sup>Arizona Cancer Center, University of Arizona, Tucson, AZ 85724

<sup>1</sup>D.L. and N.J. contributed equally to this work.

<sup>2</sup>N.L. and B.B. share senior authorship.

Received for publication December 22, 2010. Accepted for publication June 26, 2011.

This work was supported by grants from La Ligue contre le Cancer (to B.B.), the Conseil Régional de Bourgogne (to B.B.), and the University Hospital of Dijon (to B.B.), as well as National Institutes of Health Grant R01 CA104926 (to E.K. and N.L.), Arizona Cancer Center Support Grant CA023074 (to E.K. and N.L.), and funds from Tee Up for Tots and People Acting Now Discover Answers (to E.K. and N.L.).

Address correspondence and reprint requests to Prof. Bernard Bonnotte, CR INSERM 866, Institut de Recherche Fédératif 100, Faculté de Médecine, 7 Boulevard Jeanne d'Arc, 21079 Dijon, France. E-mail address: bbonnotte@u-bourgogne.fr

The online version of this article contains supplemental material.

Abbreviations used in this article: CMH, 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine; DC, dendritic cell; ESR, electron spin resonance; FasL, Fas ligand; FeTPPS, 5,10,15,20-tetrakis(4-sulfonatophenyl)prophyrinato iron (III) chloride; hKDC, human killer dendritic cell; KDC, killer dendritic cell; poly(I:C), polyinosinic:polycytidylic acid.

Copyright © 2011 by The American Association of Immunologists, Inc. 0022-1767/11/\$16.00

Importantly, after killing tumor cells, these cytotoxic DCs were able to activate tumor Ag-specific T lymphocytes.

## Materials and Methods

### Cell lines

The following human cancer cell lines were purchased from the American Type Culture Collection (Manassas, VA): the cervix carcinoma cell line HeLa, the breast adenocarcinoma cell line MCF7, and the human colorectal cancer cell lines HT29, SW480, and HCT116. The T1 melanoma cell line and the LT12 CTL clone specific for the Melan-A<sub>25–36</sub> peptide were provided by Dr. S. Chouaib (INSERM Unité 753, Villejuif, France). The human embryonic cells and the A7R5 rat vascular smooth muscle cells were provided by Dr. L. Lagrost (INSERM Unité 866, Dijon, France). HT29-expressing GFP was obtained by retroviral transfection (9). The percentage of GFP-expressing cells was measured by flow cytometry.

### Patients

Ten patients with different confirmed cancers were enrolled in the clinical study before treatment after giving their written informed consent. Lymphoma ( $n = 2$ ), pulmonary ( $n = 4$ ), or colon cancer ( $n = 4$ ) patients at stage IV incurable cancer were enrolled. None of the patients had received chemotherapy or any other immunosuppressive treatment during the previous 3 mo.

### Reagents

LPS, flagellin, poly(I:C), gardiquimod, and crystal violet were purchased from Sigma-Aldrich (St. Louis, MO). 5,10,15,20-Tetrakis(4-sulfonatophenyl)prophyrinato iron (III) chloride (FeTPPS) was obtained from Calbiochem (San Diego, CA). IFN- $\gamma$  and TNF- $\alpha$  were purchased from Pepro-Tech (Rocky Hill, NJ), CpG was from InvivoGen (Carlsbad, CA), and Pam<sub>3</sub>Cys-SK<sub>4</sub> was from EMC (Tubingen, Germany). IL-6 and IL-1 $\beta$  were purchased from R&D Systems (Minneapolis, MN) and PGE<sub>2</sub> was from Sigma-Aldrich.

### Abs and flow cytometry analysis

The following human Abs were purchased from BD Biosciences (San Jose, CA): allophycocyanin-CD1a, FITC-CD11c, FITC-CD40, FITC-CD80, FITC-CD83, FITC-CD86, FITC-HLA-DR, PE-CD14, PE-CD163, FITC-CD3, and FITC-CD56. For flow cytometry analysis, cells ( $5 \times 10^5$ ) were washed in PBS with 0.5% BSA and 0.1% sodium azide, incubated with the appropriate Ab or isotype controls for 1 h, and then washed and analyzed by flow cytometry using an LSRII (BD Biosciences).

### Generation of DCs

Human PBMCs were isolated from the blood of cancer patients or from buffy coats of healthy donors (EFS, Besançon, France) by Ficoll-Percoll density gradient centrifugation. Monocytes were purified from human PBMCs using CD14 microbeads (Miltenyi Biotec, Bergish Gladbach, Germany) according to the manufacturer's recommendations. CD14 purity was determined using flow cytometry analysis after staining with a PE-conjugated anti-CD14 Ab (BD Biosciences) and was routinely found to be >95%. Immature DCs were obtained by incubating monocytes ( $5 \times 10^5$  cells/ml) in RPMI 1640 (BioWhittaker, Basel, Switzerland) supplemented with 10% FBS and recombinant human GM-CSF (100 ng/ml) and IL-4 (20 ng/ml) (both from PromoCell, Heidelberg, Germany) for 5 d. Day 5 DCs exhibited a phenotype (low expression of costimulatory molecules such as CD40, CD80, CD83, CD86, and HLA-DR) and function (high capability of endocytosis but low IL-12 production and limited ability to induce T cell proliferation), consistent with those of immature DCs. DC maturation was triggered with LPS (100 ng/ml) or IFN- $\gamma$  (1000 IU/ml) or a mixture of activators: TNF (20 ng/ml) plus poly(I:C) (50  $\mu$ g/ml) or IL-1 $\beta$  (25 ng/ml) plus IL-6 (10 ng/ml) plus TNF- $\alpha$  (50 ng/ml) plus PGE<sub>2</sub> (1  $\mu$ g/ml) at day 5 for 48 h. Moreover, DC cultures were not contaminated with conventional cytotoxic cells such as macrophages, T lymphocytes, or NK cells (Supplemental Fig. 1A).

### Cytokine assays

The concentration of IL-12 in cell culture supernatants was determined using ELISA kits according to the manufacturer's procedures (Diaclone, Besançon, France, and Gen-Probe, San Diego, CA).

### Transwell assays

The tumor cells were plated ( $10^6$  cells/well) in 24-well plates. Untreated or LPS-activated DCs ( $5 \times 10^6$ ) were deposited in the inner chamber of

a Transwell membrane (0.45  $\mu$ m pore size) (Dutscher, Brumath, France). Cytotoxic assays were performed after 48 h.

### Cytotoxicity assays

DCs and target tumor cells were cocultured for 48 h. The number of residual adherent cells was then evaluated by crystal violet staining as previously described (50). Data are presented as the percentage of relative absorbance calculated from the formula  $A_{\text{test}}/A_{\text{control}}$ , where  $A_{\text{test}}$  is the absorbance of tumor cells cultured with DCs in the different conditions, and  $A_{\text{control}}$  is the absorbance of tumor cells cultured alone.

### Measurement of reactive oxygen and nitrogen species production by human DCs

The production of reactive oxygen and nitrogen species by cultured human DCs was evaluated with electron spin resonance (ESR) spectroscopy using 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH; Noxygen, Elzach, Germany) as the spin probe. CMH is a cell membrane-permeable hydroxylamine that can be oxidized by superoxide anions, peroxynitrites, and transition metals into a paramagnetic nitroxide (CP $^{\bullet}$ ), which forms a characteristic triplet electron paramagnetic resonance signal with a half-life of several hours (51–53). Briefly, activated and nonactivated human DCs ( $1 \times 10^6$ ) were incubated for 30 min at 37°C in a 5% CO<sub>2</sub> atmosphere with  $10^{-4}$  mol/l CMH in 200  $\mu$ l (pH 7.4) ESR Krebs-HEPES buffer containing  $5 \times 10^{-6}$  mol/l diethyldithiocarbamate and  $2.5 \times 10^{-5}$  mol/l desferrioxamine as transition metal chelators, as described elsewhere (53). After incubation, the cells and medium were immediately frozen in liquid nitrogen in polyethylene tubes and kept in liquid nitrogen until measurement. ESR spectra were recorded at 100°K using a Bruker EMX-100 spectrometer (Bruker, Wissembourg, France). ESR spectra were obtained using the following instrument settings: center field, 3330.2 g-factor; sweep width, 100 g-factor; microwave frequency, 9.378 GHz; microwave power, 20 mW; modulation amplitude, 5 g-factor; conversion time, 40.96 ms; time constant, 327.68 ms; receiver gain,  $1 \times 10^6$ . The amplitude of center field anisotropic signal was measured (arbitrary units) to determine CP $^{\bullet}$  nitroxide formation in activated or nonactivated human DCs as well as in buffer alone.

### Annexin V/propidium iodide

The percentage of apoptotic cells and necrotic cells was determined by using an FITC-conjugated Annexin V Apoptosis Detection Kit I according to the manufacturer's recommendations (BD Biosciences).

### T lymphocyte proliferation

T lymphocytes were obtained from buffy coats by using a Pan T Cell Isolation Kit (Miltenyi Biotec). T cells were then stained using a CellTrace Violet cell proliferation kit according to the manufacturer's procedure (Invitrogen, Carlsbad, CA). Labeled cells ( $1 \times 10^5$  cells/well) were cocultured with DCs ( $1 \times 10^4$ ) and cell division was detected by flow cytometry and analyzed by ModFit software after 5 d, as indicated by the manufacturer (Verity Software House, Topsham, ME).


### Statistical analyses

Unless specified, all experiments were reproduced at least three times and performed on samples from at least three different patients or healthy donors. Paired  $t$  tests were used to compare the different groups. When more than two groups were compared at the same time, we used repeated measures ANOVA tests. Results were considered statistically significant for  $p < 0.05$ . Analysis was performed with GraphPad Prism.

## Results

### LPS induces human monocyte-derived DC cytotoxic activity

We have previously reported that in rats or mice, DC killing activity can be triggered by the TLR4 ligand LPS (9, 19). To evaluate whether similar activation conditions may induce the cytotoxic potential of ex vivo-generated human monocyte-derived DCs, cells were exposed on day 5 to the indicated TLR ligands. Our results indicate that LPS was the only TLR agonist capable of triggering DC killing activity (Fig. 1A). LPS-activated day 5 DCs were able to kill several human tumor cell lines (HT29, MCF7, HeLa, HCT116, SW480) and some nonmalignant cells (Fig. 1B). Importantly, the viability of total T lymphocytes was minimally affected after culture with LPS-activated day 5 DCs (Sup-



**FIGURE 1.** Killing activity of monocyte-derived DCs from healthy donors. **A**, HT29 tumor cells were cultured alone (Control) or with day 5 monocyte-derived DCs (DC/tumor cell ratio of 5:1) with or without (Medium) the indicated TLR ligands: TLR4L, LPS (100 ng/ml); TLR5L, flagellin (100 ng/ml); TLR7L, gardiquimod (1 μg/ml); TLR3L, poly(I:C) (10 μg/ml); TLR9L, CpG (1 μg/ml); and TLR1,2,6L, PamCys<sub>3</sub>SK<sub>4</sub> (1 μg/ml). DC killing was evaluated after 48 h as reported (9, 19). \* $p < 0.05$ , \*\* $p < 0.005$  when compared with tumor cells cultured in the absence of DCs (Control) or in the presence of nonactivated DCs (Medium). **B**, Day 5 DCs were added to the indicated cancer cell lines at a DC/tumor cell ratio of 5:1 for 48 h in the absence (DC) or presence of LPS (100 ng/ml) (DC + LPS). Tumor cell viability was determined. \* $p < 0.05$ , \*\* $p < 0.005$  when compared with tumor cells cultured in DCs in the absence of LPS. **C**, HT29 tumor cells were cultured for 48 h with day 5 monocyte-derived DCs at a DC/tumor cell ratio of 5:1 in the presence of LPS at the indicated concentrations. Tumor cell survival was determined as described in *Materials and Methods*. **D**, Day 5 monocyte-derived DCs were cultured for 48 h with HT29 tumor cells in the presence of LPS at the indicated effector (DCs)/target (HT29 tumor cells) ratios and killing of tumor cells was evaluated. **E**, HT29 tumor cells were cultured for 48 h with day 5 immature monocyte-derived DCs (DC D5) or with day 7 activated DCs (DC D7) in the presence or absence of LPS. Day 7 mature DCs were obtained after exposure to different maturation stimuli such as LPS (D7 LPS), IFN- $\gamma$  (D7 IFN), TNF- $\alpha$  plus poly(I:C) (D7 TNF + PolyI:C), and IL-1 $\beta$  plus IL-6 plus TNF- $\alpha$  plus PGE<sub>2</sub> (D7 cytokine mixture). Tumor cell viability was then assessed. For all panels, data are representative of the results obtained with monocyte-derived DCs from 12 different healthy donors.

plemental Fig. 1B). Cells obtained after 3 d culture (early in the differentiation process toward DCs) did not exhibit significant tumoricidal activity after LPS activation (Supplemental Fig. 1C). Interestingly, even low concentrations of LPS were sufficient to trigger the cytotoxic function of DCs with a minimum optimal concentration between 0.01 and 0.1 μg/ml (Fig. 1C). A direct cytotoxic effect of LPS on tumor cells was excluded, as the survival of tumor cells was not affected by exposure to the TLR4 agonist for extensive periods of time (Supplemental Fig. 2A). Moreover, the pretreatment of tumor cells with LPS did not sensitize them to DC-mediated cytotoxicity (Supplemental Fig. 2B). Additionally, the results depicted in Fig. 1D indicate that the elimination of tumor cells was dependent on the effector DC/target tumor cell ratio.

The maturation state of cytotoxic DCs remains a subject of controversy. To address this issue, we investigated the cytotoxic potential of day 5 DCs and day 7 DCs that had been matured from day 5 to day 7 with different reagents such as LPS, IFN- $\gamma$ , TNF- $\alpha$  plus poly(I:C), or IL-1 $\beta$  plus IL-6 plus TNF- $\alpha$  plus PGE<sub>2</sub> (Supplemental Fig. 3A). These day 7 DCs were activated with LPS and

cultured for 48 h with tumor cells, and then survival of the tumor cells was assessed. The data presented in Fig. 1E indicate that LPS failed to trigger the killing activity of day 7 mature DCs regardless of the maturation mixture used to induce DC maturation (Fig. 1E). Only immature day 5 DCs were capable of triggering tumor cell death after activation with LPS (Fig. 1E). We therefore focused our investigation on the killing properties of LPS-activated day 5 monocyte-derived DCs (hereafter referred to as hKDCs) from healthy donors and from cancer patients.

#### *hKDCs generated from cancer patient blood monocytes exhibit cytotoxic activity against tumor cells*

The inhibition of DCs by tumors and their maintenance at a non-functional stage are two of the numerous mechanisms used by cancer cells to escape the antitumor response. These "tolerogenic" DCs, typically characterized by an immature or semimature phenotype, are capable of anergizing effector T lymphocytes and/or driving the differentiation of immunosuppressive Foxp3<sup>+</sup> regulatory T cells (54, 55). It was therefore fundamental and clinically relevant to determine whether the tumoricidal activity of



DCs generated from cancer patients was impaired. Monocyte-derived DCs generated from 10 patients with stage IV cancers (lung and colon cancers or lymphomas) were characterized by the same immature phenotype as DCs from healthy volunteers (Supplemental Fig. 3Aa, 3Ab). Upon LPS stimulation, DCs generated from cancer patients or healthy donors exhibited a similar mature phenotype and functional properties (Supplemental Fig. 3Ac–f, Supplemental Fig. 3B) and significant cytotoxic activity against tumor cells (40–80%) when activated with LPS (Fig. 2A). These results therefore indicate that the tumor killing ability of DCs generated from individuals with stage IV cancer is similar to that in DCs from healthy volunteers (Fig. 2B).

#### *hKDC cytotoxic activity depends on peroxynitrite*

We next investigated the mechanism underlying hKDC cytotoxicity. We first determined that the tumoricidal activity of hKDCs was dependent on direct cell–cell contact, as separation from their targets by a microporous membrane prevented killing of cancer cells (Fig. 3A). Death receptor ligands such as TRAIL or FasL have been reported to play a role in the cytotoxic activity of DCs (26, 32, 35, 36, 38, 43–46, 48, 49). We therefore evaluated whether the tumor killing activity of hKDCs was dependent on similar processes. Our results indicate that hKDCs were capable of eliminating tumor cell lines that are resistant to TNF, TRAIL, or FasL (data not shown). Consistent with these results, LPS-activated day 5 DCs did not secrete TRAIL or FasL (data not shown). In line with this result, annexin V and propidium iodide staining indicated that hKDCs induced the necrosis of tumor cells as evidenced by early plasma membrane disruption (Fig. 3B). Consistent with these results, z-VAD-fmk, a broad-spectrum cas-

pase inhibitor, failed at inhibiting hKDC-induced tumor cell death, thus excluding a conventional apoptotic-related process (Fig. 3C).


We and others have previously reported that NO or peroxynitrites represent critical effector molecules required for the tumoricidal activity of both rat and mouse DCs (9, 12, 19, 56). To define whether these cytotoxic products may also play a role in tumor cell killing by hKDCs, we analyzed reactive oxygen species production by these killer cells using ESR spectroscopy. ESR spectroscopy is one of the few techniques that allows the direct measurement of free radical species. However, most biological reactive oxygen and nitrogen species of interest are too short-lived to be measured directly with ESR spectroscopy. Hydroxylamine spin probes such as CMH can be oxidized by superoxide anion or peroxynitrites, giving rise to a more stable long-lived ESR-detectable  $CP^{\bullet}$  nitroxide. This allows the detection of these unstable species in cell cultures or isolated organs (57, 58). Our results indicate that both immature (day 5) and mature (day 7) DCs oxidize CMH into  $CP^{\bullet}$  in a time-dependent manner. However, after 6 h stimulation with LPS, immature day 5 DCs produced a significantly increased reactive oxygen and nitrogen species quantity, a characteristic that was lost in mature day 7 DCs (Fig. 3D). Moreover, a peroxynitrite inhibitor, FeTPPS, significantly abrogated the cytotoxic activity of hKDCs against several human tumor cells lines (Fig. 3E). We also confirmed that the cytotoxic activity of monocyte-derived DCs generated from cancer patients was inhibited by FeTPPS (Fig. 3F). These results therefore strongly suggest that hKDCs generated either from healthy donors or from cancer patients kill tumor cells by a mechanism involving peroxynitrite production.

#### *hKDCs are capable of capturing tumor cell debris and of activating tumor-specific T cells*


Whether hKDCs that had killed cancer cells are also capable of presenting tumor Ags and activating specific lymphocytes has remained controversial. A prerequisite for tumor Ag presentation to T cells is their uptake and processing by DCs. Using GFP-transfected HT29 tumor cells, we demonstrated that hKDCs were able to engulf tumor fragments from the tumor cells they had killed (Fig. 4A). Additionally, after tumor cell killing in presence of LPS, hKDCs (generated from healthy donors or cancer patients) exhibited a phenotype consistent with that of mature DCs (Fig. 4B). Following killing and the uptake of tumor cell fragments, these hKDCs retained their functional properties, as they were capable of inducing the proliferation of autologous T lymphocytes (Fig. 4C). Moreover, using the human melanoma cell line T1, we demonstrated that after killing cancer cells, KDCs were capable of inducing the activation of the tumor Ag (Melan-A<sub>25–36</sub>)-specific human CD8<sup>+</sup> T cell clone (Fig. 4D). These results thus indicate that hKDCs generated ex vivo from healthy volunteers or cancer patients that had killed tumor cells are efficient at presenting tumor Ag from the cancer cells they have killed.

## Discussion

We have previously reported that KDCs can be generated from rat (19) and mouse bone marrow (9). In the present study we provide evidence that human peripheral blood monocytes from both healthy individuals and, more clinically relevant, from patients with advanced cancer can also be driven to differentiate into potent killer DCs. The killing mechanism mediated by these hKDCs involves the production of peroxynitrites. After killing cancer cells, hKDCs are capable of capturing necrotic tumor cells and of differentiating into activated and fully functional APCs that produce IL-12, express high levels of HLA-DR and costimulatory molecules, and induce T cell proliferation. Moreover, these ex



**FIGURE 2.** Monocyte-derived DCs generated from cancer patients can be differentiated into potent hKDCs. *A*, HT29 tumor cells were cultured alone (Medium) or with monocyte-derived DCs generated from 10 cancer patients (1–10) (DC/tumor cell ratio of 5:1) in the presence (DC + LPS) or absence of LPS (DC). Tumor cell viability was determined after 48 h. \* $p < 0.05$  when compared with tumor cells cultured in absence of DCs (Medium) or with nonactivated DCs (DC). *B*, The cytotoxic activity of monocyte-derived DCs generated from 10 cancer patients was compared with the killing potential of monocyte-derived DCs generated from 12 healthy donors. The values represent the percentage of viable HT29 tumor cells after 48 h coculture with LPS-activated, monocyte-derived DCs from healthy donors or from cancer patients.




**FIGURE 3.** Human monocyte-derived DC killing activity depends on peroxynitrites. **A**, HT29 cells were cultured alone (Medium) or with monocyte-derived DCs from healthy donors in the presence (DC + LPS) or not of LPS (DC). The cells were cultured together (Control) or separated by a Transwell insert (Transwell). Tumor cell killing was determined after 48 h. **B**, HT29 tumor cells were cultured alone (Medium), with LPS, with day 5 monocyte-derived DCs from healthy donors with (DC + LPS), or without LPS (DC). After 48 h, the cells were stained with CD1a Ab and with annexin V-FITC/propidium iodide (PI). The percentage of PI<sup>-</sup>annexin V<sup>+</sup> (apoptotic) or PI<sup>+</sup>annexin V<sup>+</sup> (necrotic) tumor cells was determined after gating on CD1a-negative HT29 tumor cells. **C**, HT29 tumor cells were cultured alone (Medium), with LPS (100 ng/ml) (LPS), with day 5 monocyte-derived DCs (DC), with DCs in the presence of LPS (DC + LPS), or with DCs in the presence of LPS plus z-VAD-fmk (40  $\mu$ M) (DC/tumor cell ratio of 5:1). Tumor cell survival was determined after 48 h. **D**, Production of reactive oxygen species by nonactivated or LPS-activated human monocyte-derived DCs was determined by ESR. CMH was used as the spin probe. Day 5 monocyte-derived DCs from healthy donors were cultured with (DC + LPS) or without LPS (DC) for 6 h. Activated and nonactivated human DCs ( $2 \times 10^6$ ) were harvested and incubated with 1 mmol/l CMH. The amplitude of center field anisotropic signal was quantified in arbitrary units to determine CP\* nitroxide formation in LPS-activated or nonactivated human DCs at days 5 and 7. This experiment was done three times with DCs from three different healthy donors and from three cancer patients. \* $p < 0.05$ , \*\* $p < 0.005$ . **E**, HT29 tumor cells were cultured alone (Control) or with day 5 monocyte-derived DCs from healthy donors (DC): without LPS (Medium), with LPS, or with LPS and FeTPPS (50  $\mu$ M) (LPS + FeTPPS). Tumor cell viability was determined after 48 h. **F**, Different human tumor cell lines (HT29, HeLa, HCT116, SW480) were cocultured with LPS-activated human monocyte-derived DCs from healthy volunteers or from cancer patients in the presence (DC + LPS + FeTPPS) or absence (DC + LPS) of FeTPPS (50  $\mu$ M) (DC/tumor cell ratio of 5:1). Tumor cell viability was determined after 48 h. Similar results were obtained with DCs generated from six healthy donors and four cancer patients. \* $p < 0.05$  when compared with tumor cells cultured with activated DCs in the absence of FeTPPS.

vivo-generated hKDCs are capable of activating tumor Ag-specific CTLs, which strongly advocates for their therapeutic use in cancer patients. To facilitate the clinical application of hKDCs, we also demonstrated that KDCs could be generated in serum-free medium (Supplemental Fig. 4).

The cytotoxic activity of human immature peripheral blood monocyte-derived DCs has already been reported (27, 35, 37, 45, 46), but no or only a low killing activity at an E:T ratio of 5:1 was observed. Additionally, in these studies, LPS was used at high concentrations, ranging from 5 (27, 43) to 10  $\mu$ g/ml (37). In

**FIGURE 4.** hKDCs exhibit the phenotypal and functional characteristics of mature activated APCs after killing of tumor cells. **A**, GFP-transfected HT29 tumor cells were cultured with day 5 monocyte-derived DCs (DC) or with LPS (DC + LPS) for 72 h. The cells were then stained with CD11a Ab and analyzed by flow cytometry for GFP expression. Representative data of three experiments performed with DCs from healthy donors are shown. **B**, *Upper histograms*, Phenotype of day 5 monocyte-derived DCs (dark gray) compared with mature DCs (light gray) or hKDCs from healthy patient (black line). *Lower histograms*, Phenotype of day 5 monocyte-derived DCs (full gray) compared with hKDCs from healthy patient (black line) or from cancer patients (red line). hKDCs were collected from a 48-h culture with HT29 tumor cells and LPS. Cells were stained with the indicated Ab and analyzed by flow cytometry. **C**, Autologous T lymphocyte proliferation was assessed using a CellTrace Violet cell proliferation kit as described in *Materials and Methods*. CellTrace Violet-labeled purified T cells were cocultured with day 5 immature DCs without activator (T + DC), with LPS (100 ng/ml) (T + DC + LPS), with HT29 tumor cells (T + DC [tu]), or with HT29 tumor cells in the presence of LPS (T + DC [LPS + tu]) (DC/T cell ratio of 1:10). Non-activated T cells were used as a negative control, and T cells stimulated with anti-CD3/anti-CD28 T cell expansion beads were used as a positive control (T cells). The T cell proliferation index ( $P_i$ ) was defined after 5 d T cell/DC cocultures using ModFit software. **B** and **C**, Representative results from three experiments performed with DCs from three different healthy donors and from three different cancer patients are shown. **D**, Immature day 5 DCs were cultured with T1 melanoma cell line in the presence or absence of LPS (100 ng/ml). After 48 h, DCs were harvested from these cocultures and plated with anti-T1 CD8<sup>+</sup> T cells (CTL clone specific for Melan-A<sub>25-36</sub> peptide) for an additional 4 h (DC/T cell ratio of 5:1). TNF- $\alpha$  production by CTLs was measured using a TNF- $\alpha$  ELISA kit.



contrast to these high concentrations, we now report that LPS induces hKDC killing activity even at doses as low as 10 ng/ml. The mechanisms underlying KDC-mediated cytotoxic function have been related to death receptors and their ligands (25–27, 29, 32–36, 42, 44, 46, 47). Our results indicate that hKDCs induce tumor cell necrosis by a process that is independent of the above-mentioned mechanisms of cytotoxicity. By using the ESR technique and specific inhibitors, we identified peroxynitrites as the primary molecule responsible for KDC tumoricidal function. The inhibition of KDC killing activity by the peroxynitrite catalyst FeTPPS (59–63) confirmed the primary role of these molecules. Importantly, although the mechanism of cytotoxicity used by these hKDCs is not specific to tumor cells and may affect normal cell survival, we confirmed that no significant killing of T lymphocytes was detectable in the presence of hKDCs. This can be explained by the fact that T lymphocyte killing might be a minor phenom-

enon compared with the high proliferation rate of T cells induced by these DCs. Another explanation may stem from the fact that the high levels of proinflammatory cytokines produced by hKDCs can support T cell survival by activating anti-apoptotic mechanisms that render T lymphocytes resistant to DC-mediated cytotoxicity. In support of this hypothesis, recent studies have reported on cytokine driven upregulation of Bcl2 or related anti-apoptotic molecules in subsets of effector and memory T cells, allowing them to survive (64–66).

Whether KDCs can be generated from cancer patients has not been previously elucidated. This is a relevant question insofar as the tumor microenvironment is able to suppress many aspects of the anti-cancer immune response to escape from recognition by the immune system (67, 68). One of the mechanisms of tumor-induced immunosuppression consists in inhibiting the ability of DC precursors to differentiate into functional cells (5, 68, 69). We



therefore reasoned that the tumor killing activity of DCs generated from cancer patient monocytes may be impaired. Our results indicate that KDCs generated from all the cancer patients evaluated in this study were able to kill tumor cells, indicating that this cytotoxic potential was not inhibited by the tumor environment. Moreover, whatever the type of cancer, hematological or solid tumors, hKDCs from cancer patients were as cytotoxic as those from healthy donors. This is a clinically important finding that opens new perspectives for the use of autologous hKDCs in cancer patients. The use of hKDCs could circumvent extensive ex vivo manipulations during DC vaccine protocols, such as tumor Ag preparation and loading, and DC activation. Autologous DCs from cancer patients may be differentiated into hKDCs and activated ex vivo and then used to kill autologous tumor cells and to acquire and process released tumor Ag in vitro before being reinjected into the patient. These novel findings may be relevant for the design of new improved DC-based vaccines.

## Acknowledgments

We thank A. Morizot, P. Bastable, A. Legrand, and A. Bouchot (SERCO-BIO) for technical assistance.

## Disclosures

The authors have no financial conflicts of interest.

## References

1. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. *Nature* 392: 245–252.
2. Figdor, C. G., I. J. de Vries, W. J. Lesterhuis, and C. J. Melief. 2004. Dendritic cell immunotherapy: mapping the way. *Nat. Med.* 10: 475–480.
3. Steinman, R. M., and J. Banchereau. 2007. Taking dendritic cells into medicine. *Nature* 449: 419–426.
4. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. *Nat. Med.* 10: 909–915.
5. Adema, G. J. 2009. Dendritic cells from bench to bedside and back. *Immunol. Lett.* 122: 128–130.
6. De Vries, I. J., D. J. Krooshoop, N. M. Scharenborg, W. J. Lesterhuis, J. H. Diepstra, G. N. Van Muijen, S. P. Strijk, T. J. Ruers, O. C. Boerman, W. J. Oyen, et al. 2003. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. *Cancer Res.* 63: 12–17.
7. Janikashvili, N., N. Larmonier, and E. Katsanis. 2010. Personalized dendritic cell-based tumor immunotherapy. *Immunotherapy* 2: 57–68.
8. Chan, C. W., E. Crafton, H. N. Fan, J. Flook, K. Yoshimura, M. Skarica, D. Brockstedt, T. W. Dubensky, M. F. Stins, L. L. Lanier, et al. 2006. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. *Nat. Med.* 12: 207–213.
9. Fraszczak, J., M. Trad, N. Janikashvili, D. Cathelin, D. Lakomy, V. Granci, A. Morizot, S. Audia, O. Micheau, L. Lagrost, et al. 2010. Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. *J. Immunol.* 184: 1876–1884.
10. Huang, J., T. Tatsumi, E. Pizzoferrato, N. Vujanovic, and W. J. Storkus. 2005. Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. *Cancer Res.* 65: 8461–8470.
11. Larmonier, N., J. Fraszczak, D. Lakomy, B. Bonnotte, and E. Katsanis. 2010. Killer dendritic cells and their potential for cancer immunotherapy. *Cancer Immunol. Immunother.* 59: 1–11.
12. Serbina, N. V., T. P. Salazar-Mather, C. A. Biron, W. A. Kuziel, and E. G. Pamer. 2003. TNF/ $\alpha$ /iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. *Immunity* 19: 59–70.
13. Taieb, J., N. Chaput, C. Ménard, L. Apetoh, E. Ullrich, M. Bonmort, M. Péquignot, N. Casares, M. Terme, C. Flament, et al. 2006. A novel dendritic cell subset involved in tumor immunosurveillance. *Nat. Med.* 12: 214–219.
14. Tatsumi, T., J. Huang, W. E. Gooding, A. Gambotto, P. D. Robbins, N. L. Vujanovic, S. M. Alber, S. C. Watkins, H. Okada, and W. J. Storkus. 2003. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. *Cancer Res.* 63: 6378–6386.
15. Alli, R., B. Savithri, S. Das, C. Varalakshmi, N. Rangaraj, and A. Khar. 2004. Involvement of NKR-P2/NGK2D in DC-mediated killing of tumor targets: indicative of a common, innate, target-recognition paradigm? *Eur. J. Immunol.* 34: 1119–1126.
16. Chauvin, C., and R. Josien. 2008. Dendritic cells as killers: mechanistic aspects and potential roles. *J. Immunol.* 181: 11–16.
17. Chauvin, C., J. M. Philippeau, C. Hémond, F. X. Hubert, Y. Wittrant, F. Lamoureux, B. Trinité, D. Heymann, F. Rédini, and R. Josien. 2008. Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. *Cancer Res.* 68: 9433–9440.
18. Josien, R., M. Heslan, J. P. Souillou, and M. C. Cuturi. 1997. Rat spleen dendritic cells express natural killer cell receptor protein 1 (NKR-P1) and have cytotoxic activity to select targets via a  $\text{Ca}^{2+}$ -dependent mechanism. *J. Exp. Med.* 186: 467–472.
19. Nicolas, A., D. Cathelin, N. Larmonier, J. Fraszczak, P. E. Puig, A. Bouchot, A. Bateman, E. Solary, and B. Bonnotte. 2007. Dendritic cells trigger tumor cell death by a nitric oxide-dependent mechanism. *J. Immunol.* 179: 812–818.
20. Srivastava, R. M., Ch. Varalakshmi, and A. Khar. 2007. Cross-linking a mAb to NKR-P2/NGK2D on dendritic cells induces their activation and maturation leading to enhanced anti-tumor immune response. *Int. Immunol.* 19: 591–607.
21. Trinité, B., C. Chauvin, H. Pêche, C. Voisine, M. Heslan, and R. Josien. 2005. Immature  $\text{CD4}^+ \text{CD103}^+$  rat dendritic cells induce rapid caspase-independent apoptosis-like cell death in various tumor and nontumor cells and phagocytose their victims. *J. Immunol.* 175: 2408–2417.
22. Trinité, B., C. Voisine, H. Yagita, and R. Josien. 2000. A subset of cytolytic dendritic cells in rat. *J. Immunol.* 165: 4202–4208.
23. Ayres, F. M., M. Narita, M. Takahashi, L. Alldawi, A. Liu, Y. Osman, T. Abe, T. Yano, M. Sakaue, K. Toba, et al. 2003. A comparative study of the JAM test and  $^{51}\text{Cr}$ -release assay to assess the cytotoxicity of dendritic cells on hematopoietic tumor cells. *Immunol. Invest.* 32: 219–227.
24. Ayres, F. M., M. Narita, M. Takahashi, T. Yano, A. Liu, K. Toba, T. Furukawa, and Y. Aizawa. 2004. Human dendritic cells mediate anti-tumor activity against hematopoietic tumor cells without direct contact and Fas/FasL killing pathway. *Oncol. Rep.* 11: 1017–1023.
25. Beaulieu, S., M. Lafontaine, M. Richer, I. Courchesne, E. A. Cohen, and D. Bergeron. 1998. Characterization of the cytotoxic factor(s) released from thymic dendritic cells upon human immunodeficiency virus type 1 infection. *Virology* 241: 285–297.
26. Chaperot, L., A. Blum, O. Manches, G. Lui, J. Angel, J. P. Molens, and J. Plumas. 2006. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. *J. Immunol.* 176: 248–255.
27. Chapoval, A. I., K. Tamada, and L. Chen. 2000. In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. *Blood* 95: 2346–2351.
28. Fanger, N. A., C. R. Maliszewski, K. Schooley, and T. S. Griffith. 1999. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). *J. Exp. Med.* 190: 1155–1164.
29. Hardy, A. W., D. R. Graham, G. M. Shearer, and J. P. Herbeuval. 2007. HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN- $\alpha$ . *Proc. Natl. Acad. Sci. USA* 104: 17453–17458.
30. Hill, K. S., F. Errington, L. P. Steele, A. Merrick, R. Morgan, P. J. Selby, N. T. Georgopoulos, D. M. O'Donnell, and A. A. Melcher. 2008. OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions. *J. Immunol.* 181: 3108–3115.
31. Hubert, P., S. L. Giannini, A. Vanderplasschen, E. Franzen-Detrooz, N. Jacobs, J. Boniver, and P. Delvenne. 2001. Dendritic cells induce the death of human papillomavirus-transformed keratinocytes. *FASEB J.* 15: 2521–2523.
32. Janjic, B. M., G. Lu, A. Pimenov, T. L. Whiteside, W. J. Storkus, and N. L. Vujanovic. 2002. Innate direct anticancer effector function of human immature dendritic cells, I: Involvement of an apoptosis-inducing pathway. *J. Immunol.* 168: 1823–1830.
33. Joo, H. G., T. P. Fleming, Y. Tanaka, T. J. Dunn, D. C. Linehan, P. S. Goedegebuure, and T. J. Eberlein. 2002. Human dendritic cells induce tumor-specific apoptosis by soluble factors. *Int. J. Cancer* 102: 20–28.
34. Lichtner, M., C. Marañón, P. O. Vidalain, O. Azocar, D. Hanau, P. Lebon, M. Burgard, C. Rouzioux, V. Vullo, H. Yagita, et al. 2004. HIV type 1-infected dendritic cells induce apoptotic death in infected and uninfected primary CD4 T lymphocytes. *AIDS Res. Hum. Retroviruses* 20: 175–182.
35. Liu, S., Y. Yu, M. Zhang, W. Wang, and X. Cao. 2001. The involvement of TNF- $\alpha$ -related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN- $\beta$ -stimulated human dendritic cells to tumor cells. *J. Immunol.* 166: 5407–5415.
36. Lu, G., B. M. Janjic, J. Janjic, T. L. Whiteside, W. J. Storkus, and N. L. Vujanovic. 2002. Innate direct anticancer effector function of human immature dendritic cells, II: Role of TNF, lymphotxin- $\alpha_1\beta_2$ , Fas ligand, and TNF-related apoptosis-inducing ligand. *J. Immunol.* 168: 1831–1839.
37. Manna, P. P., and T. Mohanakumar. 2002. Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro. *J. Leukoc. Biol.* 72: 312–320.
38. Raftery, M. J., M. Schwab, S. M. Eibert, Y. Samstag, H. Walczak, and G. Schönrich. 2001. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. *Immunity* 15: 997–1009.
39. Schäkel, K., R. Kannagi, B. Kniép, Y. Goto, C. Mitsuoka, J. Zwirner, A. Soruri, M. von Kietzell, and E. Rieber. 2002. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. *Immunol.* 17: 289–301.
40. Schäkel, K., E. Mayer, C. Federle, M. Schmitz, G. Riethmüller, and E. P. Rieber. 1998. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. *Eur. J. Immunol.* 28: 4084–4093.
41. Schmitz, M., S. Zhao, Y. Deuse, K. Schäkel, R. Wehner, H. Wöhner, K. Hölig, F. Wienforth, A. Kiessling, M. Bornhäuser, et al. 2005. Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. *J. Immunol.* 174: 4127–4134.

42. Schmitz, M., S. Zhao, K. Schäkel, M. Bornhäuser, D. Ockert, and E. P. Rieber. 2002. Native human blood dendritic cells as potent effectors in antibody-dependent cellular cytotoxicity. *Blood* 100: 1502–1504.
43. Shi, J., K. Ikeda, N. Fujii, E. Kondo, K. Shinagawa, F. Ishimaru, K. Kaneda, M. Tanimoto, X. Li, and Q. Pu. 2005. Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells. *Cancer Sci.* 96: 127–133.
44. Stary, G., C. Bangert, M. Tauber, R. Strohal, T. Kopp, and G. Stingl. 2007. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. *J. Exp. Med.* 204: 1441–1451.
45. Vanderheyde, N., E. Aksoy, Z. Amraoui, P. Vandenabeele, M. Goldman, and F. Willems. 2001. Tumoricidal activity of monocyte-derived dendritic cells: evidence for a caspase-8-dependent, Fas-associated death domain-independent mechanism. *J. Immunol.* 167: 3565–3569.
46. Vanderheyde, N., P. Vandenabeele, M. Goldman, and F. Willems. 2004. Distinct mechanisms are involved in tumoricidal and tumoricidal activities of monocyte-derived dendritic cells. *Immunol. Lett.* 91: 99–101.
47. Vidalain, P. O., O. Azocar, B. Lamouille, A. Astier, C. Rabourdin-Combe, and C. Servet-Delprat. 2000. Measles virus induces functional TRAIL production by human dendritic cells. *J. Virol.* 74: 556–559.
48. Vidalain, P. O., O. Azocar, H. Yagita, C. Rabourdin-Combe, and C. Servet-Delprat. 2001. Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand. *J. Immunol.* 167: 3765–3772.
49. Yang, R., D. Xu, A. Zhang, and A. Gruber. 2001. Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs. *Int. J. Cancer* 94: 407–413.
50. Bonnotte, B., N. Favre, S. Reveneau, O. Micheau, N. Droin, C. Garrido, A. Fontana, B. Chauffert, E. Solary, and F. Martin. 1998. Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate. *Cell Death Differ.* 5: 480–487.
51. Dikalov, S., M. Skatchkov, B. Fink, and E. Bassenge. 1997. Quantification of superoxide radicals and peroxynitrite in vascular cells using oxidation of sterically hindered hydroxylamines and electron spin resonance. *Nitric Oxide* 1: 423–431.
52. Wyche, K. E., S. S. Wang, K. K. Griendling, S. I. Dikalov, H. Austin, S. Rao, B. Fink, D. G. Harrison, and A. M. Zafari. 2004. C242T CYBA polymorphism of the NADPH oxidase is associated with reduced respiratory burst in human neutrophils. *Hypertension* 43: 1246–1251.
53. Kuzkaya, N., N. Weissmann, D. G. Harrison, and S. Dikalov. 2003. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. *J. Biol. Chem.* 278: 22546–22554.
54. Steinman, R. M., D. Hawiger, and M. C. Nussenzweig. 2003. Tolerogenic dendritic cells. *Annu. Rev. Immunol.* 21: 685–711.
55. Belkaid, Y., and G. Oldenhove. 2008. Tuning microenvironments: induction of regulatory T cells by dendritic cells. *Immunity* 29: 362–371.
56. Shimamura, H., R. Cumberland, K. Hiroishi, S. C. Watkins, M. T. Lotze, and J. Baar. 2002. Murine dendritic cell-induced tumor apoptosis is partially mediated by nitric oxide. *J. Immunother.* 25: 226–234.
57. Oudot, A., C. Martin, D. Busseuil, C. Vergely, L. Demaison, and L. Rochette. 2006. NADPH oxidases are in part responsible for increased cardiovascular superoxide production during aging. *Free Radic. Biol. Med.* 40: 2214–2222.
58. Delemasure, S., P. Sicard, B. Lauzier, D. Moreau, C. Vergely, and L. Rochette. 2007. Acute administration of epirubicin induces myocardial depression in isolated rat heart and production of radical species evaluated by electron spin resonance spectroscopy. *J. Cardiovasc. Pharmacol.* 50: 647–653.
59. Bolton, C., G. S. Scott, T. Smith, and R. J. Flower. 2008. The acute and chronic phases of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE) are ameliorated by the peroxynitrite decomposition catalyst, 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinatoiron (III) chloride, (FeTPPS). *Eur. J. Pharmacol.* 601: 88–93.
60. Duplain, H., C. Sartori, P. Dessen, P. Y. Jayet, M. Schwab, J. Bloch, P. Nicod, and U. Scherrer. 2008. Stimulation of peroxynitrite catalysis improves insulin sensitivity in high fat diet-fed mice. *J. Physiol.* 586: 4011–4016.
61. Lancel, S., S. Tissier, S. Mordon, X. Marechal, F. Depondieu, A. Scherpereel, C. Chopin, and R. Neviere. 2004. Peroxynitrite decomposition catalysts prevent myocardial dysfunction and inflammation in endotoxemic rats. *J. Am. Coll. Cardiol.* 43: 2348–2358.
62. Lauzier, B., P. Sicard, O. Bouchot, S. Delemasure, D. Moreau, C. Vergely, and L. Rochette. 2007. A peroxynitrite decomposition catalyst: FeTPPS confers cardioprotection during reperfusion after cardioplegic arrest in a working isolated rat heart model. *Fundam. Clin. Pharmacol.* 21: 173–180.
63. Sharma, S. S., A. Dhar, and R. K. Kaundal. 2007. FeTPPS protects against global cerebral ischemic-reperfusion injury in gerbils. *Pharmacol. Res.* 55: 335–342.
64. Kurtulus, S., P. Tripathi, M. E. Moreno-Fernandez, A. Sholl, J. D. Katz, H. L. Grimes, and D. A. Hildeman. 2011. Bcl-2 allows effector and memory CD8<sup>+</sup> T cells to tolerate higher expression of Bim. *J. Immunol.* 186: 5729–5737.
65. Wojciechowski, S., P. Tripathi, T. Bourdeau, L. Acero, H. L. Grimes, J. D. Katz, F. D. Finkelman, and D. A. Hildeman. 2007. Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. *J. Exp. Med.* 204: 1665–1675.
66. Schluns, K. S., W. C. Kieper, S. C. Jameson, and L. Lefrançois. 2000. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. *Nat. Immunol.* 1: 426–432.
67. Gabrilovich, D. 2004. Mechanisms and functional significance of tumour-induced dendritic-cell defects. *Nat. Rev. Immunol.* 4: 941–952.
68. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. *Annu. Rev. Immunol.* 25: 267–296.
69. Bonnotte, B., M. Crittenden, N. Larmonier, M. Gough, and R. G. Vile. 2004. MIP-3 $\alpha$  transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. *J. Immunol.* 173: 4929–4935.